January 19, 2017 8:40 AM ET


Company Overview of Eris Lifesciences Private Limited

Company Overview

Eris Lifesciences Private Limited operates as a pharmaceutical company. Its products include atorsave, atorsave EZ 10/20, atorsave F, D500 cal, remylin, superclop, enoxave, obesave, glimisave 1/2/4, glimisave M1/M2, triglimisave ½, glitaris, eritel, eritel H, eritel AM, ramisave, ramisave H, lorsave, lorsave H, and metaloc. The company was founded in 2007 and is based in Ahmadabad, India.

21, New York Tower, A Wing

Near Thaltej Cross Road

Opposite Muktidham Temple

Sarkhej Gandhinagar Highway

Ahmedabad,  380055


Founded in 2007


91 79 3017 9400


91 79 3017 9404

Key Executives for Eris Lifesciences Private Limited

Eris Lifesciences Private Limited does not have any Key Executives recorded.

Eris Lifesciences Private Limited Key Developments

Eris Lifesciences Reportedly Plans IPO

Eris Lifesciences Private Limited reported that as part of the offering, ChrysCapital Management Company, is planning to sell its 16% stake in the company. Axis Capital Limited, Credit Suisse Securities (India) Private Limited and Citigroup Global Markets India Private Limited are acting as financial advisors for the offering.

ChrysCapital To Reported Exit Eris Lifesciences Via IPO

ChrysCapital intends to exit from Eris Lifesciences Private Limited through an initial public offering (IPO) and has initiated talks for the same, said three people close to the matter said. One person stated: "ChrysCapital has started discussions with several investment banks for an IPO of Eris Lifesciences. Several banks, both foreign and domestic, are expected to pitch for the mandates. The pitches will be happening over the next few weeks,” Another person stated that the size of the IPO could be around to INR 6 billion - INR 8 billion. “The IPO will be majorly an offer for sale of shares by ChrysCapital, which wants to exit its investment,” he said.

ChrysCapital In Talks To Sell Eris

ChrysCapital intends to sell its stake in Eris Lifesciences Private Limited. ChrysCapital is holding talks with Apax Partners LLC, Advent International Corporation, Multiples Alternate Asset Management Private Limited;, Baring Private Equity Asia and The Carlyle Group LP (NasdaqGS:CG) to sell its 165 stake in Eris Lifesciences. The deal is expected to be valued at $400 million-$450 million.

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Eris Lifesciences Private Limited, please visit www.eris.co.in. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.